Renal Response to CPB- Exam 1 Flashcards Preview

CV Perf Tech III > Renal Response to CPB- Exam 1 > Flashcards

Flashcards in Renal Response to CPB- Exam 1 Deck (56)
Loading flashcards...
31

Pulsatile Perfusion

Some studies say it is better
others show no idfference
no studies show it is harmful
Most cases not creating "true" pulse pressure
Adds significant degree of complexity
No significant advantage

32

Incidence of emboli and their associated clinical problems greatly reduced when...

Stopped using bubble oxygenators
Started using arterial/cardiotomy filter

33

Most patients who develop post op renal failure:

suffer form pre-existing renal disease
Have compromised renal perfusion secondary to low CO during perioperative period

34

What on bypass can cause post op renal failure ?

Low renal perfusion pressure while on bypass
Low renal perfusion pressure off pump caused by renal vasoconstriction during low cardiac output states

35

What is the goal of any pharmacological intervention?

Prevent acute renal failure that requires dialysis

36

Calcium Channel Antagonists

Nifedipine
Felodipine
Diltiazem

37

Anti-inflammatory/antioxidant drugs

Corticosteroids
Aspirin
N-acetylcysteine

38

What is an indication of renal hypoperfusion?

Monitor urine output with decreased output

39

Oliguria

U/O less than 0.25-0.33 ml/kg/hr

40

What is the relationship between intraoperative urine volume and post op renal dysfunction?

No correlation

41

Decreased urine output could be result of what?

Kinked or obstructed catheter or stress-induced ADH

42

What is the most important counter to renal hypoperfusion?

Maintaining adequate perfusion

43

Dopamine

MOA: Stimulate dopamine receptors in renal vasculature; vasodilation; inhibits sodium reabsorption in proximal tubule

Dose: 0.5 ug/kg/min

Problems: Post-Op A-fib, impairment of ventilatory drive in response to hypoxemia and hypercarbia, supress circulating levels of anterior pituitary-dependent hormones; renal effect is unpredictable

Current Research: No benefit, unpredictable

44

Fenoldopoam

Type: Synthetic benzazepine derivation

MOA: Binds selectively to DA1 receptors, causes systemic and renal vasodilation; theoretically augments RBF during CPB

Dose: 0.1 ug/kg/min
0.5 ug/kg/min

Problems: Should not be used prophylactically, further research necessary

Current ResearcH: Improvement in creatinine clearance, less renal-replacement therapy, decreased time of mechanical ventilation and ICU stay; currently no difference in ARF-D incidence

45

Dopexamine

Type: Synthetic sympathomimetic amine

MOA: stimulates B2 and dopaminergic DA1 receptors, exerting both systemic and renovasodilatory effect

Dose: 0.5 ug/kg/kim- 2.0 ug/kg/min

Problems: Only modest improvements in creatinine clearance; role is still speculative

Current Research: Potentially inhibits SIRS due to decrease in proinflammatory cytokines by B2 and DA1 receptor stimulation

46

Furosemide (Loop Diuretics)

MOA: inhibits active transcellular transport of Cl and Na, produce natriuresis

Problems: Higher rate of renal impairment compared to LDD; worsens outcome when treating oliguria

Current Research: reducing active transport decreases cellular oxygen demand and decreases damange to mTAL. May increase clearance of necrotic cellular debris diminishing tubular obstruction; improvement in urine flow rates but no change in overall dialysis-free survival

47

Mannitol (Osmotic Diuretic)

MOA: "Flushing" effect of necrotic tubular debris, oxygen-free radical scavenging and improevement in meduallary blood flow reducing endothelial edema

Dose: 0.25 - 1.0 g/kg before aortic XC

Problems: Unproven as a renal protectant

Current Studies: No greater renal protection

48

Natriuretic Peptides

MOA: Dilates afferent arterioles, increases Pgc and GFR. Inibits the tubular reabsorption of chloride and sodium, redistributes medullary BF and bloods endothelin in renal vasculature

Problems: Worse in patients with nonoliguric ARF, due to hypotension from ANP; no role in perioperative renal dysfunction

Research: Increase in dialysis-free survival only in patients with oliguric ARF.

49

Calcium Channel Antagonists

Nifedipine
Diltiazem
Felodipine

50

Nifedipine

Research: improved GFR, enhance vasodilating protraglandin E2, supress the vasoconstricting prostaglandin Thromboxane B2, modulate vascular sythesis of endothelin, improvements in postop renal function measured by creatinine clearance

51

Felodipine

Type: dihydropyridine calcium channel antagonist

MOA: preferential increase in regional blood flow to ischemic regions of hte kidneys

Research: in patients with baseline serum creatinine levels less than 1.3 mg% undergoing elective CABG with CPB. IV infusion of felodipine administered during the second half of hypothermic CPB nad discontinued before rewarming. GFR and active tubular transport improved

52

Diltiazem

Reductions in urinary microenzyme excretion

Problems: Little protection against ARF

MOA: lowers blood pressure while possibly preserving renal function

53

Anti-Inflammatory/Antioxidant Drugs

Corticosteroids
Aspirin
N-Acetylcysteine

54

Corticosteroids

Problem: Induced renal injury as evidenced by increase in urinary N-acetylglucosaminidase levels

Research: Suggests no benefit, potential harm due to the effects of hyperglycemia

55

Aspirin

Normally discontinued 7-10 days before open-heart surgery to minimize perioperative hemorrhage due to platelet dysfunction.

MOA: inhibition of thromboxane, a potent renovasoconstrictor

Dose: 100 mg until day of surgery

Potentially beneficial for preserving post op renal function.

Problems: increase in postop bleeding

Research: Significantly less postop renal insufficiency in aspirin-treated group

56

N-Acetylcysteine

MOA: Attenuating radiocontrast-induced nephropathy

Problems: should not be considered as a prophylactic renoprotective drug

Research: failed to show any benefit of therapy in at-risk patients undergoing CABG with CPB